1. Dale D, Crawford J et al. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review. Proceedings of the American Society of Clinical Oncology. 2001; 20: 410a. Abstract.
2. Aapro MS, Cameron DA et al. The European Organisation for Research and. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433–53.
3. Smith TJ, Khatcheressian J et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. J Clin Oncol 2006; 24: 3187–205.
4. Bonadonna G, Valagussa P et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. New Engl J Med 1995; 332: 901–6.
5. Budman DR, Berry DA et al. 3rd Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J National Cancer Institute 1998; 90: 1205–11.
6. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clinical Infectious Diseases. 2004; 39 (Suppl. 1): S65–7.
7. Epelbaum R, Faraggi D et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990; 66: 1124–9.
8. Kwak LW, Halpern J et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963–77.
9. Lepage E, Gisselbrecht C et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol 1993; 4: 651–6.
10. Bonadonna G, Moliterni A et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005; 330: 217–22.
11. Perez EA. TAC – a new standard in adjuvant therapy for breast cancer? N Engl J Med 2005; 352: 2346–8.
12. Martin M, Pienkowski T et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302–13.
13. G.von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56–63.
14. Martin M, Lluch A et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17: 1205–12.
15. Findlay B, Tonkin K et al. A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Ann Oncol 2007; 18 (10): 1646–51.
16. Crawford J, Ozer H et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med 1991; 325: 164–70.
17. Trillet-Lenoir V, Green J et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–24.
18. Crawford J, Althaus B et al. National Comprehensive Cancer Network. Myeloid growth factors clinical practice guidelines in oncology. J of the National Comprehensive Cancer Network. 2005; 3: 540–55.
19. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. Journal of the National Comprehensive Cancer Network. 2005; 3: 557–71.
20. Clark OAC, Lyman G, Castro AA et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. [Review]. Cochrane Database of Systematic Reviews. The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2008.
21. Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002a; 20: 727–31.
22. Almenar D, Mayans J, Juan O et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study. Eur J Cancer Care (Engl) 2009; 18 (3): 280–6.
23. von Minckwitz G, Kommel S, du Bois A et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008; 19 (2): 292–8.
24. Timmer-Bonte JN, de Boo TM, Smit HJ et al. Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974–84.
25. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). Редакторы русского перевода: проф. С.А.Тюляндин, к.м.н. Д.А.Носов, проф. Н.И.Переводчикова. М.: Издательская группа РОНЦ им. Н.Н.Блохина РАМН, 2009; с. 216–29.

М.Е.Абрамов, Л.Г.Жукова

Отделение химиотерапии и комбинированного лечения злокачественных опухолей РОНЦ им. Н.Н.Блохина РАМН, Москва